RAGE Biotech Pty Ltd is a pharmaceutical start-up company developing novel therapeutics for patients with difficult-to-treat inflammatory disease. With our proprietary RNA therapeutics and peptide technologies, we are developing drugs targeting the Receptor for Advanced Glycation End-products (RAGE), a clinically important, pro-inflammatory ‘sensing’ receptor.  Our most advanced programme is an inhaled drug for lung diseases where inflammation is a problem.  RAGE Biotech was formed in 2020 with investments from IP Group, Monash Investment Holdings, the University of Western Australia and the Perron Instute.

Biotechnology

Pharmaceutical

Therapeutics

RAGE Biotech

RAGE Biotech's headquarters in Melbourne, Australia

Description

People (5)

Christopher Wraight

Julie Monk

Kevin Pfleger

Alisa Selimovic

Siro Perez

Jobs